4basebio strengthens board with strategic appointment of biopharma leader Dr. Manja Boerman

Cambridge, UK 28 July, 2025 - 4basebio PLC (AIM: 4BB) (“4basebio”), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announced the appointment of Dr. Manja Boerman to its Board of Directors, reinforcing the company’s strategic focus on commercial growth and global market expansion.

Dr. Boerman brings over 25 years of experience in biologics and advanced therapies, having held senior executive roles at companies including Catalent, DSM Biologics, and Patheon. Her appointment comes at a pivotal time for 4basebio as the company accelerates delivery of its scalable, pDNA-free synthetic DNA platform to meet the growing needs of the cell and gene therapy sector.

Since completing its £40 million investment round in November 2024, 4basebio has reached several key milestones, including receiving MHRA GMP certification in April 2025 for the manufacture and supply of synthetic DNA for clinical use. These developments form part of a broader commercial strategy aimed at establishing 4basebio as a leading provider of synthetic DNA for advanced therapeutic applications.

“As we move into our next phase of commercial delivery, Manja’s experience at the intersection of science, strategy, and manufacturing is an ideal match for 4basebio as we accelerate our commercial growth and scale our platform” said Heikki Lanckriet, CEO of 4basebio. “Her experience in building and growing biologics manufacturing organisations will support our ambition to become the partner of choice for high-quality synthetic DNA.”

Dr. Boerman has served as President of Catalent’s Cell, Gene and Protein Therapy division and held CEO roles at Kiadis Pharma and Regenesance. She currently sits on the boards of Syngene International and Dinamiqs, contributing to strategic, technical, and ESG oversight.

Her appointment also supports the company's broader brand evolution, which includes the upcoming launch of a new visual identity and website on 1st July 2025, initiatives designed to better reflect 4basebio’s maturity and market focus.

“4basebio is uniquely positioned to address critical bottlenecks in genetic medicine manufacturing,” said Dr. Boerman. “I’m excited to support the team as they build a scalable, globally relevant offering that enables innovation across the next generation of therapies.”

About 4basebio

4basebio is a specialist life sciences company focused on the design, manufacture, and supply of synthetic DNA for use in applications such as gene therapies, mRNA therapies, and DNA vaccines. Its proprietary synthetic DNA platform enables scalable, pDNA-free manufacturing, supporting faster development and improved safety profiles for genetic medicines.

For more information, please visit www.4basebio.com or follow us on LinkedIn

Media Contact
Hannah Ingram
Hannah.ingram@4basebio.com
+44 7857 901 737